Validation of a dosage individualization table for extended-interval gentamicin in Neonates;Validación de una tabla de individualización de la administración de gentamicina en intervalo extendido en neonatos

Annals of Pharmacotherapy

Volumn 46, Issue 7-8, 2012, Pages 935-942

  Dersch Mills, Deonne ^a   Akierman, Albert ^a,b   Alshaikh, Belal ^b   Yusuf, Kamran ^b  

^a ALBERTA HEALTH SERVICES   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Administration and dosage; Aminoglycosides; Infant; Newborn; Pharmacokinetics

Indexed keywords

GENTAMICIN;

ANTIBIOTIC THERAPY; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN INTENSIVE CARE; OBSERVATIONAL STUDY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TURNAROUND TIME; VALIDATION STUDY;

EID: 84864779324     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R029     Document Type: Article

References (30)

1. Thureen PJ, Reiter PD, Gresores A, et al. Once- versus twice-daily gentamicin dosing in neonates ≥34 weeks' gestation: cost-effectiveness analyses. Pediatrics 1999;103:594-598.
2. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 2003;17:503-528.
3. Craig WA. Once-daily versus multiple-daily dosing of aminoglycosides. J Chemother 1995;7(suppl 2):47-52.
4. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004;114:111-8. doi: 10.1542/peds.114.1.e111
5. Nestaas E, Bangstad HJ, Sandvik L, et al. Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis. Arch Dis Child Fetal Neonatal Ed 2005;90:F294-F300. doi: 10.1136/adc.2004.056317
6. Rao SC, Srinivasjois R, Hagan R, et al. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Systematic Rev 2006(1): CD005091.pub2:10.1002/14651858.
7. Mercado MC, Brodsky NL, McGuire MK, et al. Extended interval dosing of gentamicin in preterm infants. Am J Perinatol 2004;21:73-77.
8. de Alba Romero C, Gomez Castillo E, Manzanares Secades C, et al. Once-daily gentamicin dosing in neonates. Pediatr Infect Dis J 1998; 17:1169-1171.
9. Hayani KC, Hatzopoulos FK, Frank AL, et al. Pharmacokinetics of once daily dosing of gentamicin in neonates. J Pediatr 1997;131:76-80.
10. Agarwal G, Rastogi A, Pyati S, et al. Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants ≥2500 g. J Perinatol 2002;22:268-74. doi: 10.1038/sj/jp/7210704
11. English M, Mohammed S, Ross A, et al. A randomised, controlled trial of once daily and multidose daily gentamicin in young Kenyan infants. Arch Dis Child 2004;89:665-669. doi: 10.1136/adc.2003.032284
12. Hale LS, Durham CR. A simple, weight-based, extended interval gentamicin dosage protocol for neonates. Am J Health Syst Pharm 2005; 62:1613-1616. doi: 10.2146/ajhp040532
13. Hansen A, Forbes P, Arnold A, et al. Once-daily gentamicin dosing for the preterm and term newborn: proposal for a simple regimen that achieves target levels. J Perinatol 2003;23:635-639.
14. Rastogi A, Agarwal G, Pyati S, et al. Comparison of two gentamicin dosing schedules in very low birth weight infants. Pediatr Infect Dis J 2002; 21:234-240.
15. Avent ML, Kinney JS, Istre GR, et al. Gentamicin and tobramycin in neonates: comparison of a new extended dosing interval regimen with a traditional multiple daily dosing regimen. Am J Perinatol 2002;19:413-419.
16. Ohler, KH, Menke JA, Fuller L. Use of higher dose extended interval aminoglycosides in a neonatal intensive care unit. Am J Perinatol 2000; 17:285-290.
17. Hoff DS, Wilcox RA, Tollefson LM, et al. Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates. Pharmacotherapy 2009;29:1297-1305.
18. Gooding N, Elias-Jones A, Shenoy M. Gentamicin dosing in neonatal patients. Pharm World Sci 2001;23:179-180.
19. Fullas F, Padomek MT, Thieman CJ, Van Gorp AE. Comparative evaluation of six extended-interval gentamicin dosing regimens in premature and full-term neonates. Am J Health Syst Pharm 2011;68:52-56. doi: 10.2146/ajhp100114
20. deHoog M, Mouton JW, Schoemaker RC, et al. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. Clin Pharmacol Ther 2002;71:349-358. doi: 10.1067/mcp.2002.123595
21. Martinkova J, Pokorna P, Zahora J, et al. Tolerability and outcomes of kinetically guided therapy with gentamicin in critically ill neonates during the first week of life. Clin Ther 2010;32:2400-414. doi: 10.1016/j.clinthera.2011.01.013
22. Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet 2009;48:71-88.
23. Boyle EM, Brookes I, Nye K, et al. Random gentamicin concentrations do not predict trough levels in neonates receiving once daily fixed dose regimens. BMC Pediatr 2006;6:8. doi: 10.1186/1471-2431-6-8
24. Murphy JE, Roether AM. Two nomograms for determining extendeddosing intervals for gentamicin in neonates. Am J Health Syst Pharm 2008;65:624-30. doi: 10.2146/ajhp.070314
25. Young TE, Mangum B, eds. Neofax 23rd ed. Montvale, NJ: Thomson Reuters, 2010:50-51.
26. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1147-1157.
27. Lacy MK, Nicolau DP, Nightingale CH, et al. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998;27:23-27.
28. Swan SK. Aminoglycoside nephrotoxicity. Semin Nephrol 1997;17:27-33.
29. Schentag JJ, Meagher AK, Jelliffe RW. Aminoglycosides. In: Burton ME, Shaw LM, Schentag JJ, et al., eds. Applied pharmacokinetics & pharmacodynamics. 4th ed. Baltimore, MD: Lippincott, Williams & Wilkins, 2006:285-327.
30. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed ototoxicity and nephrotoxicity. Antimicrob Agents Chemother 1999;43: 1549-1555.